Small molecule inhibitory antibodies (S MIAs) are a new class of anti-cancer drugs that have high promise as effective anticancer agents. An SMIA is a protein complex that recognizes specific cancer cells. Once the SMIA recognizes the cancer cell, it triggers a biological response that destroys cancer. When it comes to geographical impact, North America seems to be gaining significant traction in the small molecule cancer drugs market. This is due to large incidences of cancer across the U.S. On the contrary, Asia Pacific is showing promising signs due to improving healthcare infrastructure in India and China.
Drivers of the Global Small Molecule Cancer Drugs Market
The worldwide small molecule cancer medications market is anticipated to expand as a result of regulatory bodies giving key players approval for small molecule cancer therapies. For instance, the U.S. Food & Medication Administration (FDA) approved Piqray, a drug made by Novartis AG, in combination with fluvestrant in May 2019. It is the first medication ever made exclusively for the treatment of advanced HR/HER2-, PIK3CA-mutated breast cancer.
0
